Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
June 17, 2019 Off

Shionogi to Present Cefiderocol and COT-143 Data at American Society for Microbiology Microbe 2019 Meeting

By BusinessWire

OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced there will be one oral presentation…

June 17, 2019 Off

Shionogi to Present Cefiderocol and COT-143 Data at American Society for Microbiology Microbe 2019 Meeting

By BusinessWire

OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced there will be one oral presentation…

Arena Pharmaceuticals testing etrasimod’s potential as an important future therapy for ulcerative colitis
June 17, 2019 Off

Arena Pharmaceuticals testing etrasimod’s potential as an important future therapy for ulcerative colitis

By Dino Mustafić

Arena Pharmaceuticals has dosed first patients in a trial called ELEVATE UC 52, which is the first of two pivotal trials within the Phase 3 registrational program designated to test etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis (UC).

June 17, 2019 Off

Federal, State and Local Officials Join AMPAC Fine Chemicals in Celebrating Re-Opening of Facility Operations in Petersburg, VA

By BusinessWire

AFC will grow its pharmaceutical manufacturing capabilities with advanced technology and refreshed infrastructure, bringing more than 110 new jobs to…

Reducing severity of Rheumatoid Arthritis
June 17, 2019 Off

Reducing severity of Rheumatoid Arthritis

By Dino Mustafić

by: Lucy WyndhamYoga can Reduce the Severity of Rheumatoid Arthritis There are over 1.3 million Americans battling rheumatoid arthritis (RA)…

June 17, 2019 Off

RIBOMIC Announces Positive Top-Line Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet Age-Related Macular Degeneration

By BusinessWire

RBM-007 was well-tolerated with no dose-limiting toxicities, no systemic or ocular serious adverse events. Seven out of nine subjects showed…

ArQule’s data confirm miransertib’s potential for treating PS and PROS patients
June 17, 2019 Off

ArQule’s data confirm miransertib’s potential for treating PS and PROS patients

By BusinessWire

Encouraging preliminary safety and clinical activity data confirm miransertib’s potential for treating PS and PROS patients Registrational study, MOSAIC (Miransertib…

IVERIC bio, Catalent’s Paragon Gene Therapy in deal for Orphan Inherited Retinal Diseases
June 17, 2019 Off

IVERIC bio, Catalent’s Paragon Gene Therapy in deal for Orphan Inherited Retinal Diseases

By BusinessWire

NEW YORK & SOMERSET, N.J.–(BUSINESS WIRE)–IVERIC bio, Inc. (NASDAQ: ISEE) and Catalent Biologics, today announced that they have entered into…

Diaceutics investing another £1 million in patient data to improve outcomes
June 17, 2019 Off

Diaceutics investing another £1 million in patient data to improve outcomes

By BusinessWire

Acquisition of 16 million additional patient records per annum Creation of new partnerships with laboratories and payers across US, Asia…

June 17, 2019 Off

Dyne Therapeutics Announces Support for END-DM1 Natural History Study of Patients with Myotonic Dystrophy Type 1 (DM1)

By BusinessWire

Study sponsored by Myotonic Dystrophy Clinical Research Network will advance understanding of disease progression and enable development of clinical outcome…

Posts pagination

Previous 1 … 3,076 3,077 3,078 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine